Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NICHE trial in early-stage colon cancer
NL-OMON53138Phase 2Recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Mar 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of nivolumab, ipilimumab, celecoxib, adakitug and relatlimab in colon adenocarcinoma and colorectal cancer (CRC) (6 arms), sponsored by Netherlands Cancer Institute. Primary endpoints: Safety and feasibility and 3-year disease-free survival. Started Mar 2017; status: recruiting.
02
Drugs
03
Conditions
colon adenocarcinomacolorectal cancer (CRC)
Beyond the preview
Go deeper on NL-OMON53138.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53138.